circle-image

Short

Trend Resistance

Uptrend Above: 23850

Bull Signal Above: 24150
circle-image

Term

Trend Point Acts

Trend Point: 23770

My PCR: 0.57
1370 Range 690

Bear Market Signal

circle-image

View

Trend Suport

Down Below: 23680

Bear Signal Below: 23470
Short Term View Historic Data

Nifty View Tomorrow: Tuesday 29 Sep 2026

Day Close

22780
Day High

23080
Day Low

22762
Day Avg

22874
28 Sep 2026
5 SMA

23152
10 SMA

23212
20 SMA

23483
50 SMA

23963
200 SMA

24400
5 EMA

22964
10 EMA

22994
20 EMA

23122
50 EMA

23362
Tomorrow
Resist 2

23150
Resist 1

22970
Mid Point

22810
Suport 1

22650
Suport 2

22520
52W High

26373
52w Low

22182
52w Down

13.62%
52w Up

2.7%
Panic View
Resist 2

23510
Resist 1

23240
Mid Point

22840
Suport 1

22445
Suport 2

22240
5d High

23489
5d Low

22762
10d High

23592
10d Low

22762
Days High & Low 20d High

24143
20d Low

22762
50d High

24774
50d Low

22762
All Avg

23381
FFTH

23281
FTTL

23039
TTTH

23499
TTTL

23222
High & Low Avg TTFH

23893
TFFL

23433
High Avg

23558
Low Avg

23231
All Avg

23395
Nifty Historic Prediction Data

Nifty Last Five Days Moves

SNo. Date Day Close Day High Day Low 5 DMA 10 DMA 20 DMA 50 DMA 200 DMA
1 28 Sep 2026 22780 23080 22762 23152 23212 23483 23963 24400
2 25 Sep 2026 23140 23162 23020 23278 23274 23553 23994 24417
3 24 Sep 2026 23063 23281 23046 23320 23308 23600 24013 24431
4 23 Sep 2026 23446 23466 23349 23361 23345 23658 24033 24446
5 22 Sep 2026 23329 23489 23285 23315 23364 23702 24045 24459
Nifty Historic Data And Moving Avg

Go Back

Morepen Laboratories Limited strengthens integr...

Posted: 28 Sep 2026

Morepen Laboratories Limited strengthens integrated CDMO capabilities with first U.S. ANDA submission Milestone advances Morepen’s API-to-finished dosage development offering • First U.S. ANDA submitted for Sitagliptin Tablets USP in three strengths • Strengthens formulation, bioequivalence and regulatory dossier capabilities • Supports specialized CDMO opportunities across regulated markets Gurugram, 28th September 2026: Morepen Laboratories Limited has submitted its first Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration for Sitagliptin Tablets USP in 25 mg, 50 mg and 100 mg strengths. The submission extends the Company’s established API and CDMO expertise into integrated finished dosage development and regulatory filing.

Market Bits

"In investing, what is comfortable is rarely profitable." — Robert Arnott

Be prepared to invest in a down market and to "get out" in a soaring market, as per the philosophy of Warren Buffett.